Among men with prostate cancer that has stopped responding to hormonal therapy, the bone drug Xgevaâ„¢ (denosumab) delayed the spread of cancer to the bones. Full results from this study are expected to be presented at an upcoming medical meeting.

Androgen deprivation therapy (ADT) often plays an important role in the treatment of prostate cancer. ADT slows or stops prostate cancer growth by reducing the exposure of the prostate to testosterone. Eventually, however, prostate cancer can become resistant to ADT. This is known as hormone-refractory prostate cancer. Treatment options for hormone-refractory prostate cancer are limited, and research in this area continues.

Xgeva is a bone drug that targets a protein known as the RANK ligand. This protein regulates the activity of osteoclasts (cells that break down bone). Xgeva was recently approved for the prevention of bone complications such as fracture in patients with bone metastases from solid (not blood-related) cancers.

Some research has suggested that Xgeva may also have anti-cancer effects in the bone. If this proves to be correct, it could provide an important benefit for patients with cancers that tend to spread to the bone, such as prostate and breast cancers.

To evaluate the effect of Xgeva on the occurrence of bone metastases among men with prostate cancer, researchers conducted a Phase III clinical trial among men with hormone-refractory prostate cancer. All of the men had rapidly rising prostate-specific antigen (PSA) levels but were free of bone metastases at the start of the study. Patients received either Xgeva or a placebo.

  • Xgeva delayed the occurrence of bone metastases. Men treated with Xgeva remained alive and free of bone metastases for a median of 4.2 months longer than men treated with placebo.
  • There was no significant difference in overall survival between the Xgeva and placebo groups.
  • Side effects that were more common in the Xgeva group than in the placebo group included hypocalcemia (low levels of calcium in the blood) and osteonecrosis of the jaw (death of bone in the jaw).

These results suggest that in addition to reducing the risk of complications from bone metastases, Xgeva may also delay the development of bone metastases in high-risk patients. Full results from this study are expected to be presented at an upcoming medical meeting.

Reference: Amgen press release. XGEVAâ„¢ (denosumab) significantly improved bone metastasis-free survival in men with prostate cancer. December 13, 2010.

Copyright © 2017 . All Rights Reserved.